News | June 23, 2026
FDA advisory panel backs Moderna flu vaccine candidate for older adults
The backing comes as influenza remains a persistent public health burden
The backing comes as influenza remains a persistent public health burden
After a volatile decade in which approvals swung sharply from year to year, 2025’s total pushed past long-term norms, exceeding the 10-year average
The safety profile of the Lunsumio and Polivy combination was consistent with the known profiles of the individual study medicines
Clearing 19 biologics for Europe market
The FDA has granted Priority Review, setting a target decision date of 9 October 2026, potentially accelerating access to a new treatment option for a subset of patients with high-risk colon cancer characterized
The collaboration is focused on overcoming a major limitation in existing cancer drugs
Approval is based on results from the phase 3 OASIS 4 clinical trial
CEPI will commit up to US $50 million to fund preclinical research and Phase 1 clinical trials of Moderna’s mRNA-based vaccine candidate
This alliance, covering up to 12 antibody drugs, highlights the growing trend of large-scale collaborations between Chinese biotech firms and global pharmaceutical giants
The move marks one of the most significant coverage expansions yet in obesity care, bringing FDA-approved treatment options further into mainstream insurance plans rather than out-of-pocket reach
Subscribe To Our Newsletter & Stay Updated
